NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Intel
INTC
US Stock MarketDetailed Quotes
RPTX Repare Therapeutics
- 1.160
- -0.020-1.69%
Close Mar 3 16:00 ET
49.31MMarket Cap-0.58P/E (TTM)
1.230High1.130Low254.01KVolume1.170Open1.180Pre Close299.84KTurnover1.14%Turnover RatioLossP/E (Static)42.51MShares6.03052wk High0.33P/B25.92MFloat Cap1.06052wk Low--Dividend TTM22.34MShs Float46.440Historical High--Div YieldTTM8.48%Amplitude1.060Historical Low1.180Avg Price1Lot Size
Repare Therapeutics Stock Forum
Can Repare Therapeutics' Massive 75% Staff Cut Save Its Clinical Pipeline?
has options
$Repare Therapeutics (RPTX.US)$
nfa
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
29 seconds ago, 4:15 AM PST
Via GlobeNewswire
RPRX
Share
• Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC
• Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6...
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Realigning resources to extend runway to mid-2027
Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025
Exploring partnerships for continued development of Lunre+Camo and other assets
January 09, 2025 04:05 PM Eastern Standard Time
CAMBRIDGE, Mass. & MONTREAL--...
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
*************************************
REVERSE...
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
No comment yet